Effect and mechanism of 99TC-MDP on SAPHO syndrome

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100051450

Enrollment

Unknown

Registered

2021-09-23

Start date

2021-09-30

Completion date

Unknown

Last updated

2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) syndrome

Interventions

Experimental group:99TC-MDP

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Meet the diagnostic criteria for SAPHO syndrome; 2.Intense radioactive uptake of related osteoarthropathy on bone scan; 3.Follow-up time >=12 months; 4.Aged 18 to 70 years.

Exclusion criteria

Exclusion criteria: 1. Suppurative osteomyelitis; 2. Infectious palmoplantar pustulosis or palmoplantar keratosis; 3. Diffuse idiopathic hyperostosis; 4. Osteoarthropathy after retinoic acid treatment; 5. Gouty knee arthritis; 6. Severe liver and kidney disease; 7. Traumatic arthritis.

Design outcomes

Primary

Measure	Time frame
osteolytic lesions;	—

Secondary

Measure	Time frame
quality of life;pain;adverse events;inflammatory outcome;	—

Countries

China

Contacts

Public ContactMa Chao

Tenth People's Hospital of Tongji University

ponymachao@163.com+86 18721288964

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026